Viridian Therapeutics (VRDN) 10-Q/A 2017 Q1 Quarterly report (amended)

Exhibit 10.14

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Research Subaward Agreement Amendment
Pass-through Entity (PTE)		Subrecipient
PTE:    Yale University		Subrecipient: Miragen Therapeutics, Inc.
Address:    Office of Sponsored Projects                   25 Science Park – 3rd Floor                   150 Munson Street                   P.O. Box 208327		Address: 6200 Lookout Road
City, State, Zip+4 (Country): New Haven, CT 06520-8327		City, State, Zip+4 (Country): Boulder, CO 80301
PTE Principal Investigator (PI): [*], MD		Subrecipient Principal Investigator (PI): Rusty Montgomery, MD
PTE Federal Award No: 4UH2HL123886-03 REVISED		FAIN: UH2HL123886	Federal Awarding Agency: National Heart, Lung, and Blood Institute
Project Title: Mir-29 mimicry as a therapy for pulmonary fibrosis
Subaward Period of Performance: Start Date: 8/19/2016     End Date: 6/30/2017		Amount Funded This Action:    [*]	Amendment No:  3	Subaward No: M15A12064 (A10747)
Effective Date of Amendment: 10/27/2016				FFATA Reporting: Y
Amendment(s) to Original Terms and Conditions This Amendment revises the above-referenced Research Subaward Agreement as follows:
•     Subaward Period of Performance is extended through June 30, 2017. •     Budget Period is August 19, 2016 to June 30, 2017. •     Authorized Funding for Budget Period is [*]. •     Pre-award is authorized for July 1, 2016 to August 18, 2016.
All other terms and conditions of this Subaward Agreement remain in full force and effect.
By an Authorized Official of Pass-through Entity:		By an Authorized Official of Subrecipient:
/s/ Cheryl Magoveny	2/22/17	/s/ Jason A. Leverone		1/23/17
Name: Andrea Lozano Title:   Award Manager	Date	Name: Jason A. Leverone Title:   CFO		Date